University of Texas M.D. Anderson Cancer SPORE-Leukemia

德克萨斯大学安德森医学博士癌症孢子-白血病

• 批准号: 6786724
• 负责人: HAGOP KANTARJIAN
• 金额: $ 249.33万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-08-05 至 2008-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6786724
• 关键词: acute myelogenous leukemia; clinical research; human subject

DESCRIPTION (provided by applicant): The University of Texas M.D. Anderson Cancer Center is proposing a Specialized Program of Research Excellence (SPORE) in Leukemia. The primary goal of this Leukemia SPORE is to cultivate and facilitate innovative and significant translational research in the biologic, genetic and clinical aspects of leukemia to improve understanding, therapy, and prognosis. The multidisciplinary group of investigators in the Leukemia SPORE will accomplish this goal through effective integration of laboratory, epidemiologic and clinical investigations. Such activity will further our understanding of genetic susceptibility and leukemogenic molecular processes in leukemia, leading to novel, molecularly targeted strategies in leukemia. The SPORE is designed with 6 research projects and 3 core resources, as well as programs for developmental research and career development. The research projects are designed to target specific areas important in leukemia. Project 1 - Epigenetics of Drug Resistance in Acute Leukemia -targets methylation for therapy in leukemia Project 2 -Adoptive Cellular Therapy of Myeloid Leukemia - targets the use of MPO-Specific Cytotoxic T Lymphocytes (CTL) to treat leukemia Project 3 - Concerted Blockade of Oncoprotein Activity - targets sequential DNA, RNA and oncoprotein blockage in leukemia Project 4 -PPAR-gamma Nuclear Transcription Factor: A Novel Target for Leukemia Therapy - targets PPAR-gamma expression for leukemia therapy Project 5 - Molecular Epidemiology of AML Risk and Progression - evaluates genetic-molecular susceptibilities to development of AML through studies of relevant detoxifying and carcinogenesis-promoting pathways Project 6 - Response of AML Patients to FLT3 Inhibitors - targets FLT3 ligand inhibition in leukemias expressing FLT3 mutations or internal tandem duplication (ITD) Core and other resources are: Core A - Administration, Core B - Pathology and Tissue, Core C - Biostatistics & Data Management, Developmental Research Program, and Career Development Program. Through this leukemia SPORE, our research team will make a significant impact on leukemia prognosis.

描述（由申请人提供）：德克萨斯大学医学博士。安德森癌症中心提出了一项白血病卓越研究专业计划（SPORE）。 白血病孢子的主要目标是培养和促进白血病生物学，遗传学和临床方面的创新和重要的转化研究，以改善理解，治疗和预后。 白血病孢子的多学科研究小组将通过有效整合实验室、流行病学和临床研究来实现这一目标。 这种活性将进一步加深我们对白血病的遗传易感性和致白血病分子过程的理解，从而导致白血病的新型分子靶向策略。 SPORE设计了6个研究项目和3个核心资源，以及发展研究和职业发展计划。 这些研究项目旨在针对白血病中重要的特定领域。 项目1 -急性白血病耐药性的表观遗传学-白血病治疗的靶点甲基化 项目2 -髓性白血病的免疫细胞治疗-目标是使用MPO特异性细胞毒性T淋巴细胞（CTL）治疗白血病 项目3 -癌蛋白活性的协同阻断-靶向白血病中DNA、RNA和癌蛋白的顺序阻断 项目4 -PPAR-gamma核转录因子：白血病治疗的新靶点-靶向PPAR-gamma表达用于白血病治疗 项目5 -AML风险和进展的分子流行病学-通过相关解毒和致癌促进途径的研究，评估AML发展的遗传分子易感性 项目6 -AML患者对FLT 3抑制剂的应答-靶向表达FLT 3突变或内部串联重复（ITD）的白血病中的FLT 3配体抑制 核心资源和其他资源是：核心A -管理，核心B -病理学和组织，核心C -生物统计学和数据管理，发展研究计划和职业发展计划。 通过这个白血病孢子，我们的研究团队将对白血病预后产生重大影响。